---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-04
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 4
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 405
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 4 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 405, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) look strong, but your leading indicators (adjuster abandonment, "impossible to explain" actions in health-liability) are flashing red.

The expansion bookings are contaminated by a bundle price incentive, and the "enthusiastic comments" are likely reactions to the *promise* of a roadmap rather than the *utility* of the current tool. You do not have a growth problem; you have a **value-realization problem**.

Here is why the other options fail:
*   **Scale DraftPath Broadly:** This is the highest-risk move. If front-line adjusters are abandoning the tool after two days, scaling will only accelerate the discovery that the product is "shelfware," leading to a massive churn event next year.
*   **Usage Quality Sprint:** This measures *behavior*, not *value*. High usage by managers rerunning samples is "vanity usage"—it doesn't prove the tool helps adjusters settle claims faster or more accurately.
*   **Commercial Cleanroom:** This tests *pricing and sales positioning*. While useful, it doesn't tell you if the product actually works. If the product is fundamentally flawed for the end-user, no amount of pricing discipline will save it.
*   **Narrow to Health-Liability:** This is a premature pivot based on an anecdote. You know it's failing there, but you don't yet know if the core logic is salvageable or if it's a failure across all segments.

The **Claim File Review** is the only option that provides "ground truth." By inspecting the actual claim files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (acceptance vs. override). It will tell you if the product is actually solving a problem or if managers are simply forcing its use.

### The Trade-off
By choosing the Claim File Review, you are sacrificing **immediate commercial certainty**. You are choosing a slow, manual qualitative process over the fast quantitative data of the Usage Quality Sprint and the revenue-testing of the Commercial Cleanroom. You risk the board feeling that you are "over-analyzing" while bookings are high, and you give up the chance to immediately optimize your pricing strategy for the next fiscal year.

### The Strongest Reason Against This Recommendation
The Claim File Review is a "small N" sample. It provides deep insight but lacks statistical significance. There is a risk that the files you pull are not representative of the broader user base, leading you to make strategic pivots based on a handful of outliers rather than systemic trends.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "bundle price" accounts represent more than 50% of your total expansion revenue and the board's primary concern is immediate cash flow/valuation rather than long-term product-market fit. If the company is in a "growth at all costs" phase to secure a specific valuation milestone, the risk of product failure is secondary to the risk of missing a revenue target.
